Opthea (ASX:OPT) completed the final week-52 patient visit in Coast, the first of two phase three trials evaluating a combination therapy candidate for wet age-related macular degeneration, an eye disease that can blur vision, according to a Tuesday Australian bourse filing.
The trial is investigating the superiority and safety of its drug candidate, sozinibercept, in combination with aflibercept, compared with the standard of care alone.
The company is also conducting a concurrent phase three trial assessing the combination of sozinibercept with ranibizumab.
Beyond week 52, patients will continue to be treated for an additional year to evaluate extended safety and tolerability up to a two-year period, the filing said.
Top-line results from the Coast trial are anticipated in the second quarter.
The company's shares were up almost 1% in recent Tuesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。